Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Merck's Keytruda Lead Widens Over Competing Checkpoint Inhibitors

Feb 02 2019

• By Emily Hayes

Businessman Success. A businessman launching upwards, paperwork flying everywhere!

Related Content

Shingrix Seen Replacing Zostavax In EU & US as Shingles Standard Of Care

Jan 31 2018

Roche's Tecentriq Becomes Second In PD-1/L1 Family To Gain First-Line Lung Cancer Approval

Dec 07 2018

First-Line Ovarian Cancer Approval Solidifies Lead For AstraZeneca's Lynparza

Dec 19 2018

Merck's Keytruda Enjoys Clean Sweep In Lung Cancer, At Bristol's Expense

Apr 17 2018

Merck Looks To Add Pneumonia To Zerbaxa Label; Market Value Not Clear

Sep 12 2018

Merck's Stellar Keytruda Squamous Lung Cancer Data Refute Naysayers

May 24 2018

First In 10 Years, But Lenvima's First-Line Liver Label Could Be Challenged Soon

Aug 17 2018

New Products Soar And Old Stand Their Ground As Roche Heads Off Biosimilar Threat

Jan 31 2019

Bristol Stuck In Waiting Game As Opdivo TMB Gamble Fails To Pay Off

Jan 25 2019

Related Companies

Merck & Co., Inc.

Bristol Myers Squibb Company

Roche Holding AG

Eisai Co., Ltd.

AstraZeneca PLC

GSK plc

Bayer AG

Additional Topics

Sales & Earnings ImmunoOncology Commercial Cancer Infectious Diseases BioPharmaceutical

More from Earnings

More from Business

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window